Can I Take Magnesium with Crestor (Rosuvastatin)?

Is There a Drug Interaction Between Rosuvastatin and Magnesium?

No clinically meaningful pharmacokinetic interaction exists between rosuvastatin and supplemental magnesium when the two are taken with appropriate timing. The Crestor prescribing information specifically addresses antacids containing aluminum and magnesium hydroxide: co-administration reduced rosuvastatin Cmax by approximately 50% and AUC by approximately 20% [1]. This effect is a physical binding phenomenon in the stomach, not a metabolic interaction.

Why Antacid Data Matters for Supplements

The FDA-label interaction applies to antacid formulations (e.g., Maalox) containing magnesium hydroxide combined with aluminum hydroxide. Pure magnesium supplements (citrate, glycinate, threonate, taurate) were not tested in the same pharmacokinetic studies. The binding risk comes from the hydroxide/oxide salt forming an insoluble chelate with rosuvastatin in the alkaline environment these salts create [1].

What the Prescribing Information Recommends

AstraZeneca's label recommends administering rosuvastatin at least 2 hours after an aluminum- and magnesium-containing antacid [1]. The European Medicines Agency (EMA) summary of product characteristics for rosuvastatin echoes this guidance. Because magnesium oxide supplements share the same alkalinizing and chelating properties as antacid-grade magnesium hydroxide, extending this 2-hour window to oxide-form supplements is reasonable clinical practice.

Highly Bioavailable Forms Pose Less Risk

Organic magnesium salts (citrate, glycinate, taurate, malate) dissolve more completely in stomach acid and are less likely to form insoluble complexes with rosuvastatin. A 2019 review in Nutrients compared the bioavailability of 15 magnesium formulations and found that magnesium citrate achieved 25% to 30% higher serum levels than magnesium oxide at equivalent elemental doses [2]. For patients who want to minimize any theoretical absorption concern, choosing citrate or glycinate and still separating doses by two hours provides a wide safety margin.

Why Magnesium Matters for Statin Users

Magnesium is a cofactor in over 300 enzymatic reactions, including those governing vascular tone, glucose metabolism, and skeletal-muscle function. Patients on statins often share risk factors (hypertension, insulin resistance, metabolic syndrome) that independently deplete magnesium stores [3].

Prevalence of Magnesium Deficiency

The NHANES 2005-2016 data showed that roughly 48% of Americans consume less than the Estimated Average Requirement for magnesium from food alone [4]. Among adults with type 2 diabetes or metabolic syndrome (populations frequently prescribed rosuvastatin), the prevalence of hypomagnesemia (serum Mg <1.8 mg/dL) reaches 14% to 48% depending on the cohort studied [5].

Statins and Intracellular Magnesium

A 2013 study published in the Journal of the American College of Nutrition (N=88) found that patients on long-term statin therapy had significantly lower ionized magnesium levels compared to age-matched controls not on statins (0.53 vs. 0.58 mmol/L, P=0.01) [6]. The proposed mechanism involves statin inhibition of HMG-CoA reductase altering membrane phospholipid composition, which in turn affects magnesium transport across cell membranes. This finding has not been replicated in a large randomized trial, but it suggests that statin users may have a biological rationale for monitoring magnesium status.

Muscle Symptoms and Magnesium

Statin-associated muscle symptoms (SAMS) affect 7% to 29% of statin users depending on the definition and study design [7]. Low magnesium can independently cause muscle cramps, weakness, and fatigue. A 2017 cross-sectional analysis in Atherosclerosis (N=9,535) found that participants with serum magnesium in the lowest quartile had 1.34 times the odds of reporting myalgia compared to the highest quartile (OR 1.34, 95% CI 1.08-1.67) [8]. Some clinicians use magnesium supplementation as an adjunct strategy in patients who report mild SAMS but wish to continue statin therapy.

Cardiovascular Benefits of Magnesium Alongside Statin Therapy

Magnesium and rosuvastatin target different but complementary pathways in cardiovascular risk reduction. Rosuvastatin lowers LDL-C via hepatic HMG-CoA reductase inhibition, while magnesium influences endothelial function, blood pressure, and arrhythmia risk through its role as a natural calcium channel antagonist [9].

Blood Pressure Effects

A 2016 meta-analysis of 34 randomized controlled trials (N=2,028) published in Hypertension found that magnesium supplementation at a median dose of 368 mg/day reduced systolic blood pressure by 2.00 mmHg (95% CI 0.43-3.58) and diastolic blood pressure by 1.78 mmHg (95% CI 0.73-2.82) [10]. For a patient already on rosuvastatin for primary ASCVD prevention, this mild antihypertensive effect adds incremental benefit without pharmacologic overlap.

Coronary Heart Disease Risk

A dose-response meta-analysis of 16 prospective studies (532,979 participants) in BMC Medicine reported that each 200 mg/day increment in dietary magnesium was associated with a 22% reduction in heart failure risk (RR 0.78, 95% CI 0.69-0.89) and a 14% reduction in coronary heart disease (RR 0.86, 95% CI 0.78-0.94) [11]. These associations remained significant after adjusting for other dietary minerals, BMI, and physical activity.

Atrial Fibrillation Prevention

Magnesium deficiency is an established risk factor for atrial fibrillation. A prospective analysis from the Framingham Heart Study (N=3,530, median follow-up 20 years) found that participants with serum magnesium in the lowest quartile (<1.77 mg/dL) had a 52% higher risk of incident AF compared to the highest quartile (HR 1.52, 95% CI 1.00-2.31) [12]. Because statin users often carry concomitant AF risk factors (age, hypertension, diabetes), maintaining adequate magnesium levels is clinically relevant beyond the statin-supplement interaction question.

Magnesium, Insulin Sensitivity, and Metabolic Syndrome

Many patients prescribed rosuvastatin also have insulin resistance or prediabetes. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg increased physician-reported diabetes incidence by 25% compared to placebo (HR 1.25, 95% CI 1.05-1.49) over a median 1.9 years, a finding confirmed across the statin class in subsequent meta-analyses [13]. Magnesium may partially offset this metabolic effect.

HOMA-IR Improvement

A 2016 double-blind RCT in Diabetes & Metabolism (N=116) randomized hypomagnesemic, prediabetic participants to magnesium chloride 382 mg/day or placebo for 16 weeks. The magnesium group showed significant improvements in fasting glucose (from 110 to 100 mg/dL, P<0.005) and HOMA-IR (from 5.0 to 3.8, P<0.001) [14]. These changes are meaningful for a rosuvastatin patient with borderline glucose control.

HbA1c and Long-Term Glycemic Control

A systematic review and meta-analysis of 18 RCTs (N=894) published in the Journal of Internal Medicine found that magnesium supplementation reduced fasting glucose by 4.64 mg/dL (95% CI 1.98-7.30) and improved HOMA-IR by 0.40 (95% CI 0.08-0.71) [15]. The authors noted that benefits were strongest in participants who were magnesium-deficient at baseline, reinforcing the importance of checking serum levels before supplementing.

Practical Dosing and Timing Guide

Getting the dose and timing right eliminates the already-small absorption concern and maximizes the metabolic benefits of magnesium for statin users.

Recommended Elemental Doses

The National Institutes of Health Office of Dietary Supplements sets the Recommended Dietary Allowance at 420 mg/day for men aged 31+ and 320 mg/day for women aged 31+ [3]. The Tolerable Upper Intake Level for supplemental magnesium (not including dietary intake) is 350 mg/day; doses above this threshold increase the risk of osmotic diarrhea, particularly with magnesium oxide and citrate.

Dose-Separation Protocol

Take rosuvastatin at your usual time (most patients take it in the evening, though rosuvastatin's 19-hour half-life makes timing flexible). Take magnesium at least 2 hours before or after rosuvastatin. A practical schedule: rosuvastatin at bedtime, magnesium with dinner.

Choosing a Magnesium Form

| Form | Elemental Mg per Typical Dose | Bioavailability | GI Tolerance | Best For | |------|-------------------------------|-----------------|--------------|----------| | Magnesium citrate | 80-160 mg per capsule | High | Moderate (can loosen stools) | General supplementation | | Magnesium glycinate | 100-120 mg per capsule | High | Excellent | Muscle symptoms, sleep | | Magnesium taurate | 50-100 mg per capsule | Moderate-High | Excellent | Cardiovascular focus | | Magnesium oxide | 240-500 mg per tablet | Low (4%) | Poor (osmotic diarrhea) | Constipation relief | | Magnesium threonate | 48 mg per capsule | High (crosses BBB) | Good | Cognitive support |

For patients on rosuvastatin, magnesium glycinate or taurate offer the best combination of bioavailability, GI tolerance, and low chelation risk.

Monitoring and Lab Work

Routine monitoring ensures that supplementation stays within a safe therapeutic range and catches depletion before symptoms appear.

Baseline and Follow-Up Labs

Check serum magnesium at the same time as the lipid panel and hepatic function tests that rosuvastatin already requires. The reference range is 1.7-2.2 mg/dL (0.70-0.95 mmol/L). Serum magnesium below 1.8 mg/dL warrants supplementation; below 1.2 mg/dL requires IV repletion [3].

Limitations of Serum Magnesium

Only about 1% of total body magnesium circulates in serum, so a "normal" serum level does not rule out intracellular depletion [3]. Red blood cell (RBC) magnesium or ionized magnesium provides a better estimate of tissue stores but is not routinely available. If a patient has persistent muscle symptoms, fatigue, or insulin resistance despite a normal serum magnesium, some clinicians order RBC magnesium as a second-tier test.

Drug Interactions to Flag

Patients on rosuvastatin plus magnesium should alert their prescriber if they also take proton pump inhibitors (PPIs), loop diuretics, or thiazide diuretics, all of which deplete magnesium. A 2011 FDA Drug Safety Communication warned that PPIs used for more than one year may cause hypomagnesemia, and the combination of a PPI plus a thiazide diuretic is a particularly high-risk scenario [16]. The prescriber may increase the magnesium dose or switch to a better-absorbed form.

When to Avoid or Adjust Magnesium Supplementation

Magnesium is not appropriate for every patient on Crestor. Certain clinical situations require dose adjustment or avoidance.

Renal Impairment

Patients with an eGFR <30 mL/min/1.73 m² should not supplement magnesium without nephrology guidance. The kidneys are the primary route of magnesium excretion, and accumulation can cause hypermagnesemia (flushing, hypotension, respiratory depression) [3]. Rosuvastatin itself requires dose adjustment in severe renal impairment (maximum 5 mg/day for eGFR <30), so these patients are already under closer monitoring.

Concurrent Use of Magnesium-Sparing Drugs

Amiloride and potassium-sparing diuretics reduce renal magnesium excretion. Adding a magnesium supplement on top of these agents can push serum levels above 2.6 mg/dL. Check serum magnesium 2-4 weeks after starting supplementation in any patient on a potassium-sparing diuretic.

Signs of Magnesium Excess

Early symptoms include nausea, facial flushing, and drowsiness. Serum levels above 4.0 mg/dL can produce loss of deep tendon reflexes, and levels above 6.0 mg/dL risk cardiac arrest [3]. These thresholds are essentially unreachable with oral supplementation in patients with normal kidney function, but they underscore why renal status matters.